Welcome to our dedicated page for BillionToOne SEC filings (Ticker: BLLN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page is intended to provide access to U.S. Securities and Exchange Commission (SEC) filings for BillionToOne, Inc. (NASDAQ: BLLN), a Menlo Park, California-based molecular diagnostics company. BillionToOne focuses on prenatal and oncology testing built on its patented Quantitative Counting Templates (QCT) molecular counting platform, and its regulatory filings offer additional detail on its business, risks, and financial profile.
In registration statements and related prospectus materials filed in connection with its initial public offering on the Nasdaq Global Select Market, the company describes its mission to create powerful and accurate tests that are accessible to all. These filings discuss the role of the QCT platform, which BillionToOne characterizes as the only multiplex technology that can accurately count DNA molecules at the single-molecule level, and outline how this technology supports products such as the UNITY Complete non-invasive prenatal test and Northstar liquid biopsy assays.
Over time, investors can expect BillionToOne’s SEC filings to include annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K, along with any registration statements or proxy materials the company submits. These documents typically provide information on revenue sources across prenatal clinical testing, oncology clinical testing, and other services, as well as details on operating expenses, liquidity, and risk factors, as reflected in the company’s public financial communications and prospectus.
On Stock Titan, SEC filings for BLLN are supplemented with AI-powered summaries that explain key sections in plain language. Real-time updates from EDGAR help surface new filings as they become available, while AI-generated highlights can draw attention to topics such as segment performance, capital structure, and material events disclosed by BillionToOne in its official documents.
BillionToOne, Inc. filed a current report stating that it issued a press release on January 12, 2026, reiterating its guidance for the full year ended December 31, 2025 and initiating guidance for full year 2026. This means the company confirmed its prior outlook for 2025 while also providing its initial expectations for 2026.
The company also noted that the investor presentation used at the 2026 J.P. Morgan Healthcare Conference on January 12, 2026 will be posted on the Investor page of its website under the “Events & Presentations” section.
BillionToOne, Inc. (BLLN) filed a Form 4 reporting equity award activity for its Chief Financial Officer. The filing shows stock options with exercise prices of $11.55 and $30.78 covering 175,000 and 75,000 shares, respectively. These options are listed both before and after a reclassification in connection with the company’s initial public offering of Class A common stock.
The filing explains that, under a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically converted into one share of Class A common stock immediately prior to completion of the IPO. The $11.55 options vest over four years, with 25% vested on January 8, 2025 and the rest in monthly installments over three years. The $30.78 options vest in equal monthly installments over four years starting September 15, 2025, contingent on continued service.